IDYA (IDEAYA Biosciences Inc) שולי הרווח הגולמי

סמל תאגידי ולוגו של IDEAYA Biosciences Inc (IDYA)

IDEAYA Biosciences (IDYA) laid its growth foundation by attracting leading chemists and oncologists through generous stock options, as evidenced by the peak in final gross margin. Revenue is now driven by the commercialization of targeted therapies for rare tumors. The current level of 87.70 reflects the parameter's status amid stringent FDA regulatory filters and closed B2B partnerships that determine the company's survival.

IDYA - רווחיות לפי רווח גולמי ideayabio.com בטווח 04.07.2022 - 19.11.2026

פילוחי מדדים פיננסיים ומדדי שוק עבור IDEAYA Biosciences (IDYA)

- שער מניה ותחזית מחירי מומחים:
- מדדי הערכת שווי שוק של העסק:
הערכת שווי פונדמנטלית:IDYA IDEAYA Biosciences Inc
סחורת הדגל של IDEAYA Corp

Fundamental asset screening requires an assessment of the efficiency of direct production cost management. By analyzing gross margin trends, an investor determines the profit share after deducting the cost of goods sold, which for IDEAYA Biosciences (IDYA) reflects the high added value of drugs protected by biomarker patents and multi-billion dollar R&D investments that preclude the emergence of cheap generics.